Last updated on February 2018

Cognitive Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease


Brief description of study

Cognitive Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease

Detailed Study Description

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in an early stage AD population.

Clinical Study Identifier: TX144012

Find a site near you

Start Over

The NeuroCognitive Institute

111 Howard Blvd, Suite 204 Mt. Arlington, NJ USA
  Connect »

Bradenton Research Center

909 Hyde Street Suite 322 Bradenton, FL USA
  Connect »

Renew Behavioral Health, Inc.

909 Hyde Street Suite 322 Long Beach, CA USA
  Connect »